THE PROSTATE CANCER SYMPOSIUM
A Multidisciplinary Approach
Day One – Thursday, February 22, 2007
Biology, Epidemiology, and the Management of Early Disease
Exhibit Hall Open
7:00 AM – 6:30 PM
General Poster Session A
7:00 AM – 8:00 AM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
Breakfast Available
7:00 AM – 8:00 AM
Welcome
7:50 AM – 8:00 AM
General Session I: Etiology and Molecular Genetics
8:00 AM – 9:25 AM
Moderator: Jack Schalken, PhD – Radboud University Nijmegen Medical Center
Inflammation and Prostate Carcinogenesis
Angelo DeMarzo, MD, PhD – John Hopkins University
Is Prostate Cancer a Viral Disease?
Eric A. Klein, MD – Cleveland Clinic Foundation
Genetic Biomarkers: Promises for Individualized Cancer Therapy
Olli Kallioniemi, MD, PhD – VTT/Biotechnology and University of Turku, Finland
Question and Answer Session
Abstract Presentation
Break
9:25 AM – 9:45 AM
General Session II: Beyond PSA: Risk Prediction in the Next Decade
9:45 AM – 11:00 AM
Moderator: Anthony V. D’Amico, MD, PhD – Dana Farber Cancer Institute
Emerging Diagnostic Serum Biomarkers – EPCA-2, PSA Isoforms
Robert Getzenberg, PhD – John Hopkins Hospital
Molecular Markers: Diagnosis and Prognosis
Arul Chinnaiyan, MD, PhD – University of Michigan
Outcome Prediction Models
Kevin Slawin, MD – Baylor College of Medicine
Emerging Assays: Circulating Tumor Cells
Robert L. Vessella, PhD – University of Washington
Question and Answer Session
SUO Special Lecture: The Role of PSA in Screening and Early Detection of Prostate Cancer
11:00 AM – 11:30 AM
Introduction: Martin Gleave, MD, FRCSC, FACS – Vancouver Hospital and Health Sciences Centre
Lecture: Fritz H. Schröder, MD, PhD – Erasmus Universiteit Rotterdam
Lunch
11:30 AM – 1:00 PM
General Poster Session A
11:30 AM – 1:00 PM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
Oral Abstract Presentation Session A
1:00 PM – 2:10 PM
Moderator: Jonathan Wilson Simons, MD – Prostate Cancer Foundation
Break
2:10 PM – 2:30 PM
General Session III: Who Doesn’t Need Treatment?
2:30 PM – 4:00 PM
Moderator: Martin Gleave, MD, FRCSC, FACS – Vancouver Hospital and Health Sciences Centre
Active Surveillance in Low-Risk Disease: Who Doesn’t Need Treatment?
Chris Parker, MD, MRCP, FRCR – Institute of Cancer Research and Royal Marsden NHS Foundation Trust
Active Surveillance in Low-Risk Disease: Who Does Need Treatment?
Peter Scardino, MD, FACS – Memorial Sloan-Kettering Cancer Center
Is Active Surveillance an Opportunity for Tertiary Prevention?
Neil Fleshner, MD, MPH, FRCSC – University of Toronto
Abstract Presentation
Question and Answer Session
Break
4:00 PM – 4:15 PM
General Session IV: Panel Discussion: Debate Issues in Health-Related Quality of Life
4:15 PM – 5:30 PM
Moderator: Deborah Kuban, MD – M. D. Anderson Cancer Center
The Burden of Over-Treatment of Low Risk Prostate Cancer
David C. Miller, MD, MPH – UCLA Department of Urology
Health-Related Quality of Life After Surgery for Localized Disease
David Penson, MD, MPH – University of Southern California Norris Cancer Center
Health-Related Quality of Life After Radiation Therapy for Localized Disease
Jeff Michalski, MD – Washington University School of Medicine
Panel Discussion: Which Choice Leads to a Life Least Bothered After Prostate Cancer Therapy?
Moderator: Ian Tannock, MD, PhD – Princess Margaret Hospital
General Poster Session A (Wine & Cheese Reception)
5:30 PM – 6:30 PM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
Day Two – Friday, February 23, 2007
Contemporary Clinical Issues
Best of Journals Breakfast Session
6:45 AM – 7:45 AM
Exhibit Hall Open
7:00 AM – 6:30 PM
Breakfast Available
7:00 AM – 8:00 AM
General Poster Session B
7:00 AM – 8:00 AM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
Welcome
7:50 AM – 8:00 AM
General Session V: Additional Treatment for Pathologic T3 Disease: Now, Later, or Never
8:00 AM – 9:25 AM
Moderators: Anthony Zietman, MD – Massachusetts General Hospital
E. David Crawford, MD – University of Colorado Health Science
Center
Extracapsular Disease and the Positive Margin
David Grignon, MD – Wayne State University
Adjuvant Therapy After Surgery for High-Risk Prostate Cancer: EORTC Trial
Michel Bolla, MD – CHU de Grenoble
Adjuvant Therapy After Surgery for High-Risk Prostate Cancer: SWOG Trial
Gregory Swanson, MD – The University of Texas Health Science Center at San Antonio
Discussant
David P. Dearnaley, MD, FRCA, FRCR – Institute of Cancer Research/Royal Marsden Hospital, UK
Questions and Answer Session
Break
9:25 AM – 9:45 AM
ASTRO Special Lecture: How the RTOG Has and Will Further Change Your Practice
9:45 AM – 10:10 AM
Introduction: William U. Shipley, MD – Massachusetts General Hospital
Lecture: Howard Sandler, MD – University of Michigan Medical School
General Session VI: Androgen Deprivation in Advanced Disease: Sooner or Later?
10:10 AM – 11:30 AM
Moderator: Matthew Smith, MD, PhD – Massachusetts General Hospital
Early Intervention with Rising PSA
E. David Crawford, MD – University of Colorado Health Science Center
Delayed Intervention with Rising PSA
Derek Raghavan, MD, PhD, FACP, FRACP – Cleveland Clinic Taussig Cancer Center
Early versus Late Hormone Therapy in Node Positive Disease and in Older Men
Urs Studer, MD – University of Bern
Question and Answer Session
Fellows Luncheon Lunch
11:30 AM – 1:00 PM
General Poster Session B
11:30 AM – 1:00 PM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
Oral Abstract Presentation Session B
1:00 PM – 2:10 PM
Moderator and Discussant: Christopher Sweeney, MBBS – Indiana University
Break
2:10 PM – 2:30 PM
General Session VII: Chemotherapy: Soup to Nuts
2:30 PM – 4:00 PM
Moderators: Maha Hussain, MD, FACP – University of Michigan
Cora Sternberg, MD, FACP – San Camillo Forlanini Hospital
Current Standard of Care: Docetaxel and Beyond
Daniel George, MD – Duke Medical Center
What Are the Best Targets for Investigational Therapy?
Johann de Bono, MD, FRCP, PhD, MSc – Royal Marsden Hospital and The Institute of Cancer Research
Challenging Cases
Bruce Roth, MD – Vanderbilt-Ingram Cancer Center
Abstract Presentation
Question and Answer Session
Break
4:00 PM – 4:15 PM
General Session VIII: Sex, Lies, and Hormones
4:15 PM – 5:30 PM
Moderator: James E. Montie, MD – University of Michigan Cancer Center
Treatment-Related Diabetes and Cardiovascular Disease: Are Some Men Dying for a Lower PSA?
Matthew Smith, MD, PhD – Massachusetts General Hospital
Family Care for Patients and Spouses
Laurel Northouse, PhD, RN, FAAN – University of Michigan
Sex Life After a Saved Life
Arthur L. Burnett, II, MD– Johns Hopkins Medical Institutions
Question and Answer Session
General Poster Session B (Wine & Cheese Reception)
5:30 PM – 6:30 PM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
Day Three – Saturday, February 24, 2007
New Frontiers: Emerging Concepts in Diagnosis and Treatment
Best of Journals Breakfast Session
6:45 AM – 7:45 AM
No Exhibits
Breakfast Available
7:00 AM – 8:00 AM
General Poster Session C
7:00 AM – 8:00 AM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
Welcome
7:50 AM – 8:00 AM
General Session IX: Focal and Highly Localized Therapy
8:00 AM – 9:40 AM
Moderators: W. Robert Lee, MD – Duke University
Focal Therapy versus Extirpative Therapy
Joseph Smith, MD – Vanderbilt University Medical Center
Future Developments in Radiotherapy
Juanita Crook, MD – Princess Margaret Hospital
Question and Answer Session
Abstract Presentation
Looking Into a Crystal Ball: Treatment of Localized Prostate Cancer in 2020
Freddie Hamdy, MD – University of Sheffield Medical School
Question and Answer Session
Break
9:40 AM – 10:00 AM
General Session X: Imaging and Novel Therapeutics
10:00 AM – 11:40 AM
Moderators: Tomasz M. Beer, MD – Oregon Health and Science University
Kevin Kelly, DO– Yale School of Medicine
Transitional Research and Pathways: An Overview
David Agus, MD – Cedars Sinai Prostate Cancer Center
Imaging Targeted Therapy with Positron Emission Tomography
Steve Larson, MD – Memorial Sloan-Kettering Cancer Center
Novel Agents: Endpoints & Trial Design
Kim N. Chi, MD, FRCPC – British Columbia Cancer Agency
Panel Discussion/Question and Answer Session
Abstract Presentation
Abstract Discussion
Tomasz M. Beer, MD – Oregon Health & Science University
Question and Answer Session
Lunch
11:40 AM – 1:00 PM
General Poster Session C
11:40 AM – 1:00 PM
Selected topic-related abstracts will be on display, with the authors available for informal discussion.
ASCO Special Lecture: Diagnosis and Treatment of Men with Prostate Cancer: Can We Afford the Future?
1:00 PM – 1:30 PM
Introduction: Ian Tannock, MD, PhD – Princess Margaret Hospital
Lecture: Tomas J. Smith, MD – Virginia Commonwealth University
Oral Abstract Presentation Session C
1:30 PM – 2:40 PM
Moderator: Ian Tannock, MD, PhD – Princess Margaret Hospital
Break
2:40 PM – 3:00 PM
General Session XI: Imaging and Beyond: How Will Novel Diagnostics and Therapeutics Help with Management of Difficult Cases?
3:00 PM – 4:30 PM
Moderators: John M. Fitzpatrick, MD – British Journal of Urology International
Mario A. Eisenberger, MD – Johns Hopkins University
Review of Imaging Modalities for Prostate Cancer
Jurgen J. Fütterer, MD, PhD – University Medical Center in Nijmegen
Question and Answer Session
Panel Discussion with Audience Participation
Case Presentation 1: Small Amount of Disease on Biopsy, and Disparately High PSA
Case Presentation 2: Climbing PSA After Local Therapy
Case Presentation 3: Local Failure After Radiation Therapy
Discussants: Deborah Kuban, MD – M. D. Anderson Cancer Center
Eric J. Small, MD – University of California San Francisco
Adam Stuart Kibel, MD, PhD Washington University School of Medicine
Meeting Adjourns
4:30 PM
|
